Liver biopsy is not routine during bariatric surgery. Alanine aminotransferase (ALT) is widely
used to screen for liver disease. We assessed the relationship between ALT and pathology …

The growth of the field of hepatology over the past 30 years has largely been driven by the
burgeoning incidences and prevalences of two diseases: hepatitis C and nonalcoholic fatty …

Background Obesity is a known risk factor for nonalcoholic fatty liver disease (NAFLD).
However, among individuals undergoing bariatric surgery, the prevalence and risk factors …

Background In patients with clinically severe obesity, metabolic associated fatty liver disease
(MAFLD) and steatohepatitis are highly prevalent. There is a lack of prospective studies …

Background: Non-alcoholic fatty liver disease is common. However, little is known about
liver disease in the morbidly obese. Methods: 75 subjects (78% female, mean BMI 57 [40 …

Nonalcoholic fatty liver disease (NAFLD) is a metabolic complication of obesity that
encompasses a spectrum of conditions, including hepatic steatosis, nonalcoholic …

Background Nonalcoholic steatohepatitis is observed in 25%–55% of patients with severe
obesity and in 2%–12% with bridging fibrosis or cirrhosis. There is currently no noninvasive …

Introduction Ten percent of cirrhotic patients are known to have a high risk of postoperative
complications. Ninety percent of bariatric patients suffer from non-alcoholic fatty liver disease …

Bariatric and metabolic surgery is associated with significant improvement in obesity-related
comorbidities, but for patients with non-alcoholic fatty liver disease (NAFLD), clinical …

Non-alcoholic fatty liver disease and non-alcoholic steato-hepatitis are common in patients
undergoing bariatric surgery. Non-alcoholic steato-hepatitis can progress to cirrhosis of the …